Department of Dermatology, Seoul National University College of Medicine, Institute of Human-Environment Interface Biology, Seoul National University, Seoul, Korea.
Dermatology. 2013;226(3):227-32. doi: 10.1159/000349984. Epub 2013 Jun 14.
Masseter hypertrophy can be ameliorated by botulinum toxin.
To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy.
Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study.
Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements.
Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A.
肉毒毒素可改善咬肌肥大。
比较瑞马唑仑毒素 B（BTX-B）和肉毒毒素 A（BTX-A）治疗咬肌肥大的疗效和安全性。
16 名双侧咬肌肥大的女性患者在 24 周的双盲随机分面研究中，按 1:50 或 1:70 的剂量比分别接受 BTX-A 或 BTX-B 的单次注射。
BTX-A 和 BTX-B 均能显著改善咬肌肥大。通过计算机断层扫描（CT）测量，在 12 周时，BTX-A 和 BTX-B 按 1:70 的剂量比（分别为 15.6%和 14.2%）的最大体积减少量相当。在 24 周时，只有 BTX-A 治疗的咬肌保持显著的体积减少。研究者评估和患者满意度评分与客观 CT 测量结果平行。
BTX-A 和 BTX-B 均对治疗咬肌肥大有效。BTX-B 的剂量比为 1:70，疗效相当，但作用持续时间比 BTX-A 短。
